Loading…
Lexeo Therapeutics, Inc. is projected to decline to $4.79 by 2027, a -1% move from its current price of $4.82. LXEO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $4.64 | $4.82 | $5.00 | -0.03% |
| Jul 14 | $4.57 | $4.82 | $5.08 | -0.06% |
| Jul 15 | $4.51 | $4.82 | $5.14 | -0.09% |
| Jul 16 | $4.46 | $4.81 | $5.19 | -0.12% |
| Jul 17 | $4.42 | $4.81 | $5.24 | -0.15% |
| Jul 18 | $4.39 | $4.81 | $5.28 | -0.18% |
| Jul 19 | $4.35 | $4.81 | $5.32 | -0.21% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.35 | $4.81 | $5.32 | -0.21% |
| Week 2 | $4.17 | $4.80 | $5.53 | -0.42% |
| Week 3 | $4.03 | $4.79 | $5.69 | -0.63% |
| Week 4 | $3.91 | $4.78 | $5.84 | -0.83% |
| Week 5 | $3.82 | $4.77 | $5.96 | -1.04% |
| Week 6 | $3.73 | $4.76 | $6.08 | -1.25% |
| Week 7 | $3.65 | $4.75 | $6.19 | -1.45% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company focused on hereditary and acquired diseases with high unmet need in the United States.
Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy.
In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate.
The company was founded in 2017 and is headquartered in New York, New York.
Lexeo Therapeutics, Inc. is publicly tracked in the healthcare space with a current price of $4.82 and a market cap of $378.47M, ranking at 3264.
The near-term price outlook places the 2026 average price at $4.82, with a 30-day window ranging from $4.13 to $6.19 and a 0% ROI, reflecting a neutral stance in the immediate horizon.
Longer-term forecasts point to a material rise in value across the late 2020s and into the 2030s and beyond, with the 2030 average price at $5.39 and an 11.8% ROI; 2031 at an average of $6.31 with 30.9% ROI; 2032 at $6.84 with 41.9% ROI. The trajectory remains bullish into the mid-2030s and onward, with 2040 averaging $9.77 (102.6% ROI) and 2050 averaging $16.07 (233.5% ROI).
A major floor 25.4% below — a decisive break under it would weaken the trend.
The nearest floor, 14.3% below — buyers have tended to step in here.
The nearest ceiling, 9.5% above — a clean break opens room to run.
A major ceiling 54.4% above — clearing it would confirm fresh momentum.
Key LXEO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LXEO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.91 | Sell | $4.90 | Sell |
| MA 10 | $4.79 | Buy | $4.84 | Sell |
| MA 20 | $4.77 | Buy | $4.82 | Buy |
| MA 50 | $5.02 | Sell | $5.08 | Sell |
| MA 100 | $5.67 | Sell | $5.64 | Sell |
| MA 200 | $7.12 | Sell | $6.15 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.42 | Neutral |
| Stoch RSI (14) | 47.13 | Neutral |
| CCI (20) | 19.40 | Neutral |
| Williams %R (14) | -55.42 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | -2.03 | Sell |
| Bollinger %B (20,2) | 0.56 | Neutral |
| Stochastic %K (14) | 44.58 | Neutral |
| TRIX (15) | -0.20 | Sell |
| Awesome (5,34) | 0.15 | Buy |
| Ultimate (7,14,28) | 51.69 | Neutral |
| Momentum (10) | 0.12 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 5.13 | Sell |
| ADX (14) | 11.54 | Neutral |
| ATR (14) | 0.19 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 50 and the stock trades around the 50-day average, with a SMA50 of $5.02 and a SMA200 of $7.12.
Key support sits at $4.13 and resistance at $5.28, framing a near-term range that spans $3.76 to $6.18 over the last 30 days.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.13 | $4.82 | $6.19 | 0% | Neutral | |
| $3.68 | $4.79 | $6.68 | -1% | Neutral | |
| $3.25 | $4.40 | $6.44 | -9% | Neutral | |
| $3.28 | $4.61 | $6.99 | -4% | Neutral | |
| $3.72 | $5.38 | $8.43 | +12% | Neutral | |
| $4.24 | $6.30 | $10.14 | +31% | Bullish | |
| $4.49 | $6.85 | $11.30 | +42% | Bullish | |
| $4.07 | $6.36 | $10.73 | +32% | Bullish | |
| $4.08 | $6.52 | $11.21 | +35% | Bullish | |
| $4.22 | $6.91 | $12.11 | +43% | Bullish | |
| $5.37 | $9.76 | $18.47 | +103% | Bullish | |
| $7.30 | $16.09 | $33.97 | +234% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $4.13 | $4.82 | $5.85 | +0.00% |
| August 2026 | $4.10 | $4.89 | $6.02 | +1.41% |
| September 2026 | $3.90 | $4.69 | $5.87 | -4.04% |
| October 2026 | $3.78 | $4.60 | $5.82 | -2.01% |
| November 2026 | $3.90 | $4.77 | $6.10 | +3.70% |
| December 2026 | $3.89 | $4.79 | $6.19 | +0.55% |
Click any year to see its month-by-month LXEO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Lexeo Therapeutics, Inc.'s 2026 outlook centres on $4.82, within a $4.13 to $6.19 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, LXEO could reach as high as $6.68, with a base case around $4.79 and support toward $3.68 — roughly -1% from $4.82. Price action looks broadly range-bound.
Expect LXEO to range from $3.25 to $6.44 through 2028. The $4.40 average target implies a -9% move from current prices. That is -8% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The LXEO price prediction for 2029 points to an average of $4.61 (low $3.28, high $6.99) — a potential decline of -4% on today's $4.82. Price action looks broadly range-bound.
In 2030, LXEO is projected to trade between $3.72 and $8.43, averaging $5.38 — a potential gain of +12% from today's $4.82. That is up +17% on the projected 2029 average. A consolidation phase looks the most probable path here.
Lexeo Therapeutics, Inc.'s 2031 outlook centres on $6.30, within a $4.24 to $10.14 range. That is up +17% on the projected 2030 average. That marks a +31% change versus current levels. Momentum favours further upside here.
By 2032, LXEO could reach as high as $11.30, with a base case around $6.85 and support toward $4.49 — roughly +42% from $4.82. Buyers look set to stay in control over this stretch.
Expect LXEO to range from $4.07 to $10.73 through 2033. The $6.36 average target implies a +32% move from current prices. That is -7% versus the projected 2032 average. Momentum favours further upside here.
The LXEO price prediction for 2034 points to an average of $6.52 (low $4.08, high $11.21) — a potential gain of +35% on today's $4.82. Buyers look set to stay in control over this stretch.
In 2035, LXEO is projected to trade between $4.22 and $12.11, averaging $6.91 — a potential gain of +43% from today's $4.82. That is up +6% on the projected 2034 average. Momentum favours further upside here.
Lexeo Therapeutics, Inc.'s 2040 outlook centres on $9.76, within a $5.37 to $18.47 range. That is up +41% on the projected 2035 average. That marks a +103% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, LXEO could reach as high as $33.97, with a base case around $16.09 and support toward $7.30 — roughly +234% from $4.82. Momentum favours further upside here.
Investing $1,000 in LXEO today (≈ 207.46888 LXEO) could be worth
$3,337.19
+$2,337.19 (+234%) by 2050 · US Dollar
Based on the average projected LXEO price of $16.09 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LXEOwould be worth at today's price.
$1,000 invested in LXEO on Jul 10, 2025 (≈ 217.864917 LXEO) would be worth
$1,050.11
+$50.11 (+5.0%) today · 1.05× · US Dollar
Based on a LXEO entry price of $4.59 vs. today's $4.82.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.69 | $1,027.72 | +2.8% |
| 1 month ago | $4.13 | $1,167.07 | +16.7% |
| 3 months ago | $5.98 | $806.02 | -19.4% |
| 6 months ago | $8.12 | $593.6 | -40.6% |
| 1 year ago | $4.59 | $1,050.11 | +5.0% |
| All time (2.7y) ago | $10.05 | $479.6 | -52.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LXEO forecast.
Our base-case forecast reaches $9.60 around 2040.
Implied market cap at $9.60: $753.81M
The multi-year view shows a shift from neutral near-term sentiment to bullish momentum in the longer term. The 2030 forecast places the average price at $5.39 with an 11.8% ROI, signaling upside potential as the years progress. The 2031 forecast strengthens to an average of $6.31 with a 30.9% ROI, followed by 2032 at $6.84 with a 41.9% ROI and 2033 at $6.37 with a 32.1% ROI.
The growth continues through 2034 ($6.53 avg, 35.5% ROI) and 2035 ($6.90 avg, 43.1% ROI), before the longer-term climate turns markedly more favorable: 2040 averages $9.77 with a 102.6% ROI, and 2050 averages $16.07 with a 233.5% ROI. Notably, some early-year years show negative returns, with 2027 at -0.7% ROI, 2028 at -8.6%, and 2029 at -4.6%, illustrating that the forecast includes near-term variability within an overall upward trajectory.
Tap a question to reveal the answer.
2030 avg $5.39; min $3.73; max $8.44; ROI 11.8%; sentiment NEUTRAL.
Near-term sentiment is NEUTRAL, with a longer-run bullish path indicated from 2031 onward (2031 avg $6.31; ROI 30.9%; 2040 avg $9.77; ROI 102.6%; 2050 avg $16.07; ROI 233.5%). Note that some years such as 2027-2029 show negative ROI.
Yes. The forecast shows max prices above $10 in multiple years: 2031 max $10.16; 2032 max $11.28; 2033 max $10.74; 2034 max $11.23; 2035 max $12.09; 2040 max $18.48; 2050 max $33.94.
Current price $4.82; Market cap $378.47M; Rank 3264.
Bullish sentiment appears starting 2031 with avg $6.31 and ROI 30.9%, continuing through 2040 (avg $9.77, ROI 102.6%) and 2050 (avg $16.07, ROI 233.5%).
Lexeo Therapeutics, Inc. Community Discussion
0Share your Lexeo Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.